Bill Activity

Bill Enacted

This bill was enacted into law on 2022-09-30

Contributions

Individuals

There were no contributions to this bill.

You must be logged in to contribute

Main Subject: Economics and Public Finance

Affordable Insulin Now Act

This bill limits cost-sharing for insulin under private health insurance and the Medicare prescription drug benefit.

Specifically, the bill caps cost-sharing under private health insurance for a month's supply of selected insulin products at $35 or 25% of a plan's negotiated price (after any price concessions), whichever is less, beginning in 2023.

The bill caps cost-sharing under the Medicare prescription drug benefit for insulin products at (1) $35 in 2023 regardless of whether a beneficiary has reached the annual out-of-pocket spending threshold, and (2) $35 beginning in 2024 for those who have not yet reached this threshold.

Currently, the Centers for Medicare & Medicaid Services is testing a voluntary model under the Medicare prescription drug benefit (the Part D Senior Savings Model) in which the copayment for a month's supply of insulin is capped at $35 through participating plans. The model is set to expire on December 31, 2025.

HRES1017-117, S3700-117, HR7497-117, HR5376-117, SCONRES45-117, HR7721-117, HR7783-117, HR8684-117, S4186-117, S4535-117, S4729-117, S4785-117, S4958-117,

Library of Congress Actions

President
Sep. 30 2022	Became Public Law No: 117-180. Signed by President. Presented to President.

BecameLaw
Sep. 30 2022	Became Public Law No: 117-180. Signed by President.

NotUsed
Sep. 30 2022	Resolving differences -- House actions: On motion that the House agree to the Senate amendment Agreed to by the Yeas and Nays: 230 - 201 (Roll no. 476).

Floor
Sep. 29 2022	Passed/agreed to in Senate: Passed Senate under the order of 9/29/2022, having achieved 60 votes in the affirmative with an amendment by Yea-Nay Vote. 72 - 25. Record Vote Number: 351.

House floor actions Actions

Floor

Sep. 30
2022

Presented to President.
POSTPONED PROCEEDINGS - At the conclusion of debate on the motion to agree to the Senate amendment to H.R. 6833, the Chair put the question on agreeing to the motion and by voice vote, announced that the ayes had prevailed. Mrs. Granger demanded the yeas and nays and the Chair postponed further proceedings until a time to be announced.
DEBATE - Pursuant to H. Res. 1404, the House proceeded with one hour of debate on the motion to agree to the Senate amendment to H.R. 6833.

ResolvingDifferences
Sep. 30 2022	Motion to reconsider laid on the table Agreed to without objection. On motion that the House agree to the Senate amendment Agreed to by the Yeas and Nays: 230 - 201 (Roll no. 476). The previous question was ordered pursuant to the rule. Ms. DeLauro moved that the House agree to the Senate amendment. (consideration: CR H8330-8350, H8354-8355)

Senate Actions

Floor

Sep. 29
2022

Message on Senate action sent to the House.
Passed Senate under the order of 9/29/2022, having achieved 60 votes in the affirmative with an amendment by Yea-Nay Vote. 72 - 25. Record Vote Number: 351.
Cloture motion on the measure withdrawn by unanimous consent in Senate.
Motion by Senator Schumer to commit to Senate Committee on Appropriations with instructions to report back forthwith with the following amendment (SA 6031) withdrawn in Senate.
Considered by Senate.

Sep. 28
2022

Cloture motion on the measure presented in Senate. (CR S5148)

House bill HR6833-117

To amend title XXVII of the Public Health Service Act, the Internal Revenue Code of 1986, and the Employee Retirement Income Security Act of 1974 to establish requirements with respect to cost-sharing for certain insulin products, and for other purposes.

House bill HR6833-117

To amend title XXVII of the Public Health Service Act, the Internal Revenue Code of 1986, and the Employee Retirement Income Security Act of 1974 to establish requirements with respect to cost-sharing for certain insulin products, and for other purposes.

Promote the cause!

Or use this QR code